System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maria Lorenza Muiesan is an expert in Cardiology at Spedali Civili di Brescia (Italy). As of October 2026, ScienceLeadR ranks Maria Lorenza Muiesan in the top 1% of experts worldwide for Hypertensive Crisis, Cardiomegaly and Hypertension. Maria Lorenza Muiesan has authored 620 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 4 of them ongoing. SLR score: 1,917 (community average: 125). How the SLR is computed.

LeadR Profile

Maria Lorenza Muiesan Spedali Civili di Brescia Italy
1 917 ScienceLeadR Reputation 1917

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Hematology - Internal Medicine - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1988 - 2026
Source: PubMed

University of Brescia

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 620

Citations

Citations: 50 213 1st author: 82 Last author: 111 Unique author: 7

Main journals

J Hypertens 152
High Blood Press Cardiovasc Prev 59
Artery Res 28
Hypertension 25
Intern Emerg Med 23

Best Journals

Lancet 8
Nature 4
Eur Heart J 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Prescription of SGLT-2 inhibitors alone or in combination with RAS-inhibitors in patients with diabetes mellitus and comorbid cardiovascular disease, chronic kidney disease or cardiorenal disease: a real-world evidence study from the REPOSI registry.
PMID 42642609 — diabetes mellitus, registries, kidney diseases, sodium-glucose transporter 2 inhibitors, chronic disease, heart diseases, internal medicine, heart, cardiovascular diseases, prescriptions, kidney, aged		Intern Emerg Med20260
Clinically recognized sepsis in older adults admitted to medical wards: patient characteristics and hospital outcomes from the REPOSI register.
PMID 42635922 — mortality, internal medicine, hospital mortality, sepsis, multimorbidity, therapeutics, infections		Intern Emerg Med20260
Pathophysiology and Clinical Relevance of Microvascular Remodeling in Arterial Hypertension.
PMID 42536280 — hypertension, arteries		High Blood Press Cardiovasc Prev20260
Orthostatic Hypotension in Hypertensive Patients Hospitalized in Italian Internal Medicine Departments: FADOI-HYP-OP Study.
PMID 42455464 — adrenergic agents, comorbidity, blood, internal medicine, blood pressure, receptors, adrenergic, hypotension, orthostatic, prevalence, hypotension		High Blood Press Cardiovasc Prev20260
Central Systolic Blood Pressure and Left Ventricular Mass: Findings From the International 24-Hour Aortic Blood Pressure Consortium.
PMID 42396797 — hypertension, hypertrophy, left ventricular, heart diseases, blood, blood pressure, phenotype, hypertrophy, echocardiography		J Am Heart Assoc20261

Clinical Studies 18

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 10
Phase 3 6
Phase 2 2

By status:

Completed 11
Active not recruiting 3
Recruiting 2
Unknown 2

By type:

Interventional 9
Observational 9

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 2
multicentric5to9 0
multicentricup10 12

Main Topics

Cohort/Consortium Investigators 6

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
HF POLARIS A research study to look at how well NNC0487 0111 works compared to placebo in people with heart failure and obesity
2025-523717-29-00 — mortality, safety, heart failure, heart, heart failure, diastolic, obesity, morbidity, research		Phase 3Recruiting2026
A randomized double blind placebo controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high risk primary prevention patients (VICTORION 1 PREVENT)
2022-502779-40-00 — cardiovascular diseases, primary prevention		Phase 3Active not recruiting2023
A trial to learn how safe baxdrostat is and how well it works in adults with primary aldosteronism
2025-520740-16-00 — aldosterone, safety, hyperaldosteronism		Phase 3Active not recruiting2025
How Complexity and Multiple Illnesses Affect Hospitalized Patients Health a Multicenter Study
NCT06872632 — mortality, hospitalization, internal medicine, multimorbidity, prospective studies		N/ARecruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS